Abstract
Background: Genetic susceptibility in lung cancer risk has long been recognized but remains ill defined, as does the role of tobacco smoke exposure and chronic obstructive pulmonary disease (COPD). Methods: Using a dual case-control design, we tested whether alpha1-antitrypsin deficiency (α1ATD) carriers are predisposed to a higher risk of lung cancer, adjusting for the effects of tobacco smoke exposure and COPD. A total of 1856 patients with incident lung cancer were included in the study; 1585 community residents served as controls. A second control group was composed of 902 full siblings of the patients. We first modeled 1585 case-control pairs without the α1ATD variable using multiple logistic regression analysis and then modeled the α1ATD allele type in the presence of other known risk factors of lung cancer. Results: We found a significantly increased lung cancer risk among α1ATDcarriers from 2 parallel case-control comparisons: when patients were compared with unrelated controls, α1ATD carriers had a 70% higher risk of developing lung cancer than noncarriers (odds ratio, 1.7; 95% confidence interval, 1.2-2.4). In a further comparison of patients with their cancer-free siblings, we found a 2-fold increased lung cancer risk in α1ATDcarriers (95% confidence interval, 1.4-2.7). Stratified analysis by tumor histologic subtypes showed a significant increase for adenocarcinoma and squamous cell carcinoma among α1ATD carriers. Conclusion: Our results suggest that α1ATD carriers are at a 70% to 100% increased risk of lung cancer and may account for 11% to 12% of the patients with lung cancer in our study.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1097-1103 |
| Number of pages | 7 |
| Journal | Archives of Internal Medicine |
| Volume | 168 |
| Issue number | 10 |
| DOIs | |
| State | Published - May 26 2008 |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
Cite this
Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. / Yang, Ping; Sun, Zhifu D; Krowka, Michael Joseph; Aubry, Marie Christine; Bamlet, William R.; Wampfler, Jason A.; Thibodeau, Stephen N; Katzmann, Jerry A.; Allen, Mark S.; Midthun, David Eric; Marks, Randolph Stuart; De Andrade, Mariza.
In: Archives of Internal Medicine, Vol. 168, No. 10, 26.05.2008, p. 1097-1103.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk
AU - Yang, Ping
AU - Sun, Zhifu D
AU - Krowka, Michael Joseph
AU - Aubry, Marie Christine
AU - Bamlet, William R.
AU - Wampfler, Jason A.
AU - Thibodeau, Stephen N
AU - Katzmann, Jerry A.
AU - Allen, Mark S.
AU - Midthun, David Eric
AU - Marks, Randolph Stuart
AU - De Andrade, Mariza
PY - 2008/5/26
Y1 - 2008/5/26
N2 - Background: Genetic susceptibility in lung cancer risk has long been recognized but remains ill defined, as does the role of tobacco smoke exposure and chronic obstructive pulmonary disease (COPD). Methods: Using a dual case-control design, we tested whether alpha1-antitrypsin deficiency (α1ATD) carriers are predisposed to a higher risk of lung cancer, adjusting for the effects of tobacco smoke exposure and COPD. A total of 1856 patients with incident lung cancer were included in the study; 1585 community residents served as controls. A second control group was composed of 902 full siblings of the patients. We first modeled 1585 case-control pairs without the α1ATD variable using multiple logistic regression analysis and then modeled the α1ATD allele type in the presence of other known risk factors of lung cancer. Results: We found a significantly increased lung cancer risk among α1ATDcarriers from 2 parallel case-control comparisons: when patients were compared with unrelated controls, α1ATD carriers had a 70% higher risk of developing lung cancer than noncarriers (odds ratio, 1.7; 95% confidence interval, 1.2-2.4). In a further comparison of patients with their cancer-free siblings, we found a 2-fold increased lung cancer risk in α1ATDcarriers (95% confidence interval, 1.4-2.7). Stratified analysis by tumor histologic subtypes showed a significant increase for adenocarcinoma and squamous cell carcinoma among α1ATD carriers. Conclusion: Our results suggest that α1ATD carriers are at a 70% to 100% increased risk of lung cancer and may account for 11% to 12% of the patients with lung cancer in our study.
AB - Background: Genetic susceptibility in lung cancer risk has long been recognized but remains ill defined, as does the role of tobacco smoke exposure and chronic obstructive pulmonary disease (COPD). Methods: Using a dual case-control design, we tested whether alpha1-antitrypsin deficiency (α1ATD) carriers are predisposed to a higher risk of lung cancer, adjusting for the effects of tobacco smoke exposure and COPD. A total of 1856 patients with incident lung cancer were included in the study; 1585 community residents served as controls. A second control group was composed of 902 full siblings of the patients. We first modeled 1585 case-control pairs without the α1ATD variable using multiple logistic regression analysis and then modeled the α1ATD allele type in the presence of other known risk factors of lung cancer. Results: We found a significantly increased lung cancer risk among α1ATDcarriers from 2 parallel case-control comparisons: when patients were compared with unrelated controls, α1ATD carriers had a 70% higher risk of developing lung cancer than noncarriers (odds ratio, 1.7; 95% confidence interval, 1.2-2.4). In a further comparison of patients with their cancer-free siblings, we found a 2-fold increased lung cancer risk in α1ATDcarriers (95% confidence interval, 1.4-2.7). Stratified analysis by tumor histologic subtypes showed a significant increase for adenocarcinoma and squamous cell carcinoma among α1ATD carriers. Conclusion: Our results suggest that α1ATD carriers are at a 70% to 100% increased risk of lung cancer and may account for 11% to 12% of the patients with lung cancer in our study.
UR - http://www.scopus.com/inward/record.url?scp=44349108422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44349108422&partnerID=8YFLogxK
U2 - 10.1001/archinte.168.10.1097
DO - 10.1001/archinte.168.10.1097
M3 - Article
C2 - 18504338
AN - SCOPUS:44349108422
VL - 168
SP - 1097
EP - 1103
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 10
ER -